Merck results beat expectations despite a big drop in sales of Covid antiviral treatment

[ad_1] Merck on Thursday reported first-quarter revenue and adjusted earnings that topped Wall Street’s expectations, despite a steep drop in sales of its Covid antiviral treatment molnupiravir. Sales of molnupiravir plunged…

Biotech stocks that could surge more than 35% include one name targeting treatments for schizophrenia

[ad_1] With new drug launches and product approvals on the horizon, some biotechnology stocks could finally be due for a breakout, market participants say. Biotech investors could use a break.…